Business Description
Glaukos Corp
NAICS : 339112
SIC : 3845
ISIN : US3773221029
Description
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.77 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.83 | |||||
| Debt-to-EBITDA | -4.67 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 5.73 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.7 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year EPS without NRI Growth Rate | -1 | |||||
| 3-Year FCF Growth Rate | -33.8 | |||||
| 3-Year Book Growth Rate | -13.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 20.87 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.87 | |||||
| 9-Day RSI | 59.37 | |||||
| 14-Day RSI | 59.89 | |||||
| 6-1 Month Momentum % | 32.24 | |||||
| 12-1 Month Momentum % | 91.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.34 | |||||
| Quick Ratio | 4.78 | |||||
| Cash Ratio | 3.99 | |||||
| Days Inventory | 192.71 | |||||
| Days Sales Outstanding | 44.62 | |||||
| Days Payable | 56.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -0.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.99 | |||||
| Operating Margin % | -40.9 | |||||
| Net Margin % | -42.79 | |||||
| FCF Margin % | -24.79 | |||||
| ROE % | -27.3 | |||||
| ROA % | -13.97 | |||||
| ROIC % | -21.66 | |||||
| ROC (Joel Greenblatt) % | -59.52 | |||||
| ROCE % | -13.4 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.38 | |||||
| PB Ratio | 10.58 | |||||
| Price-to-Tangible-Book | 43.44 | |||||
| EV-to-EBIT | -42.57 | |||||
| EV-to-EBITDA | -62.26 | |||||
| EV-to-Revenue | 16.25 | |||||
| EV-to-Forward-Revenue | 14.23 | |||||
| EV-to-FCF | -65.54 | |||||
| Price-to-Projected-FCF | 51.28 | |||||
| Earnings Yield (Greenblatt) % | -2.35 | |||||
| FCF Yield % | -1.56 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers